In late August 2015, the US FDA issued a warning that drugs like sitagliptin, saxagliptin, linagliptin, alogliptin, and other DPP-4 inhibitors could cause joint pain that can be severe and disabling
First, healthy-user bias is a major concern: individuals prescribed newer, more expensive agents such as semaglutide may systematically differ from comparator groups in terms of health behaviors, dietary patterns, physical activity, adherence to medical care, and access to healthcare resources
Reduce the look of both surface-level and deep-seated spots
It works for heart failure and CKD patients regardless of diabetes status
They focused on those who prescribed semaglutide
At the heart of these lawsuits is the accusation that Novo Nordisk failed to adequately warn users about the risks associated with Ozempic, particularly concerning Gastroparesis a condition that can cause stomach paralysis